Medical Treatment of Osteoporosis/Prevention of Falls

Hyoung Keun Oh

doi:10.12671/jkfs.2018.31.4.165

Journal List > J Korean Fract Soc > v.31(4) > 1105028

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Oh: Medical Treatment of Osteoporosis/Prevention of Falls

Review Article

Journal of the Korean Fracture Society 2018; 31(4): 165-171.

Published online: 25 October 2018

DOI: https://doi.org/10.12671/jkfs.2018.31.4.165

Medical Treatment of Osteoporosis/Prevention of Falls

Hyoung Keun Oh, M.D.

Department of Orthopedic Surgery, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.

Correspondence to: Hyoung Keun Oh, M.D. Department of Orthopedic Surgery, Ilsan Paik Hospital, Inje University College of Medicine, 170 Juhwa-ro, Ilsanseo-gu, Goyang 10380, Korea. Tel: +82-31-910-7968, Fax: +82-31-910-7967, osd11@paik.ac.kr

The Korean Fracture Society

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The prevention and treatment of fragility fractures is evolving continuously. Adequate fracture care should involve treating the fracture itself as well as the underlying bone disease. Although effective treatments of osteoporosis are available, a large proportion of patients with fragility fractures are not prescribed anti-osteoporotic medications after their injury. Recent advances in diagnostic tools and medications allow for a more effective and comprehensive treatment of fragility fractures.

Keywords: Osteoporosis, Drug therapy, Falls

Notes

^{Financial support} None.

^{Conflict of interests} None.

References

1. Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int. 2004; 15:120–124.

2. Eriksen EF, Lyles KW, Colón-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009; 24:1308–1313.

3. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357:1799–1809.

4. Amanat N, McDonald M, Godfrey C, Bilston L, Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007; 22:867–876.

5. Hegde V, Jo JE, Andreopoulou P, Lane JM. Effect of osteoporosis medications on fracture healing. Osteoporos Int. 2016; 27:861–871.

6. Chang JS. Osteoporotic facture-medical treatment. J Korean Fract Soc. 2010; 23:326–340.

7. Yang KH. Anti-osteoporotic drugs and fracture healing mechanism. J Korean Fract Soc. 2011; 24:212–216.

8. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361:756–765.

9. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007; 22:1832–1841.

10. Han SL, Wan SL. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract. 2012; 66:199–209.

11. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013; 382:50–56.

12. Kim KM, Choi HS, Choi MJ, Chung HY. Calcium and vitamin D supplementations: 2015 position statement of the Korean Society for Bone and Mineral Research. J Bone Metab. 2015; 22:143–149.

13. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016; 374:254–262.

14. Grossman DC, Curry SJ, Owens DK, et al. Interventions to prevent falls in community-dwelling older adults: US preventive services task force recommendation statement. JAMA. 2018; 319:1696–1704.

15. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA. 2004; 291:1999–2006.

16. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009; 20:315–322.

17. Goldhahn J, Little D, Mitchell P, et al. Evidence for anti-osteoporosis therapy in acute fracture situations: recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Bone. 2010; 46:267–271.

18. Moroni A, Faldini C, Hoang-Kim A, Pegreffi F, Giannini S. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am. 2007; 89:96–101.

19. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab. 2015; 22:151–165.

20. Min BW, Koo KH, Park YS, et al. Scoring system for identifying impending complete fractures in incomplete atypical femoral fractures. J Clin Endocrinol Metab. 2017; 102:545–550.

21. Yang KH, Min BW, Ha YC. Atypical femoral fracture: 2015 position statement of the Korean Society for Bone and Mineral Research. J Bone Metab. 2015; 22:87–91.

22. Yoo JH, Moon SH, Ha YC, et al. Osteoporotic fracture: 2015 position statement of the Korean Society for Bone and Mineral Research. J Bone Metab. 2015; 22:175–181.

23. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010; 25:404–414.

24. Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011; 93:1583–1587.

25. Im GI, Lee SH. Effect of teriparatide on healing of atypical femoral fractures: a systemic review. J Bone Metab. 2015; 22:183–189.

26. Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012; 27:2429–2437.

27. Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012; 94:2113–2119.

28. Chu LW, Chi I, Chiu AY. Falls and fall-related injuries in community-dwelling elderly persons in Hong Kong: a study on risk factors, functional decline, and health services utilisation after falls. Hong Kong Med J. 2007; 13:Suppl1. S8–S12.

29. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012; (9):CD007146.

30. Cumming RG, Ivers R, Clemson L, et al. Improving vision to prevent falls in frail older people: a randomized trial. J Am Geriatr Soc. 2007; 55:175–181.

31. Lord SR, Dayhew J, Howland A. Multifocal glasses impair edge-contrast sensitivity and depth perception and increase the risk of falls in older people. J Am Geriatr Soc. 2002; 50:1760–1766.

32. Marsh JL, Karan MD. Fractures in the elderly patient. In : Rockwood CA, Green DP, Court-Brown CM, Heckman JD, McQueen MM, editors. Rockwood and Green's fractures in adults. 8th ed. Philadelphia: Lippincott;2016. p. 621–650.

TOOLS

ORCID iDs: Hyoung Keun Oh
https://orcid.org/0000-0001-5388-7096
Similar articles